Interleukin-10 knockout mouse: A model for studying bone metabolism during intestinal inflammation

Inflammatory Bowel Diseases

Volumn 10, Issue 5, 2004, Pages 557-563

  Cohen, Stacey L ^a   Moore, Aideen M ^b   Ward, Wendy E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bone biomechanics; Bone mass; Inflammation; Interleukin 10 knockout mice; Intestine

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BODY SIZE; BONE DENSITY; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE STRENGTH; COLON INJURY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENTERITIS; FEMALE; FEMUR; HISTOPATHOLOGY; KNOCKOUT MOUSE; LOADING TEST; LUMBAR VERTEBRA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING; WEIGHT; WILD TYPE;

ANIMALS; BIOMECHANICS; BONE DENSITY; BONE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; FEMUR; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; LUMBAR VERTEBRAE; MALE; MICE; MICE, KNOCKOUT; SEX FACTORS;

EID: 4644356719     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200409000-00009     Document Type: Article

References (48)

1. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J. Gastroenterol. 1998;93: 1483-1490.
2. Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int. 1995;5:156-160.
3. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut. 2002;51: 654-658.
4. Dinca M, Fries W, Luisetto G, et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol. 1999;94:1292-1297.
5. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233.
6. Habtezion A, Silverberg MS, Parkes R, et al. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis. 2002;8:87-92.
7. Thearle M, Horlick M, Bilezikian JP, et al. Osteoporosis: an unusual presentation of childhood Crohn's disease. J Clin Endocrinol Metab. 2000; 85:2122-2126.
8. Boot AM, Bouquet J, Krenning EP, et al. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut. 1998;42:188-194.
9. Cowan FJ, Warner JT, Dunstan FD, et al. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997;76:325-329.
10. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995;108: 417-422.
11. Bernstein CN, Leslie WD, Taback SP. Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease. Am J Gastroenterol. 2003;98:1094-1100.
12. Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2001;4:561-569.
13. American Gastroenterological Association medical position statement. Guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:791-794.
14. De Vos M, De Keyser F, Mielants H, et al. Review article: Bone and joint diseases in inflammatory bowel disease. Aliment Pharmacol Ther. 1998; 12:397-404.
15. Daci E, van Cromphaut S, Bouillon R. Mechanisms influencing bone metabolism in chronic illness. Horm Res. 2002;58:44-51.
16. Vestergaard P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur J Gastroenterol Hepatol. 2003;15:851-856.
17. Salamone LM, Whiteside T, Friberg D, et al. Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int. 1998;63:466-470.
18. Hyams JS, Wyzga N, Kreutzer DL, et al. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr. 1997;24:289-295.
19. Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur J Gastroenterol Hepatol. 2003;15:857-864.
20. Azuma Y, Kaji K, Katogi R, et al. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000; 275:4858-4864.
21. Jimi E, Nakamura I, Duong LT, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res. 1999;247:84-93.
22. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol. 1990;145:3297-3303.
23. Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab. 2001;86:957-964.
24. Heaney RP, Abrams S, Dawson-Hughes B, et al. Peak bone mass. Osteoporos Int. 2000;11:985-1009.
25. Madsen KL. Inflammatory bowel disease: lessons from the IL-10 gene-deficient mouse. Clin Invest Med. 2001;24:250-257.
26. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology. 1999;116: 1107-1114.
27. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996;98:1010-1020.
28. Madsen KL, Doyle JS, Tavernini MM, et al. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. Gastroenterology. 2000;118: 1094-1105.
29. Watanabe N, Ikuta K, Okazaki K, et al. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig Dis Sci. 2003;48:408-414.
30. Hibi T, Ogata H, Sakuraba A. Animal models of inflammatory bowel disease. J Gastroenterol. 2002;37:409-417.
31. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999;11:648-656.
32. Madsen KL, Fedorak RN, Tavernini MM, et al. Normal breast milk limits the development of colitis in IL-10-deficient mice. Inflamm Bowel Dis. 2002;8:390-398.
33. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
34. Maity S, Ukil A, Karmakar S, et al. Thearubigin, the major polyphenol of black tea, ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. Eur J Pharmacol. 2003;470:103-112.
35. Bourreille A, Doubremelle M, de la Bletiere DR, et al. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Scand J Gastroenterol. 2003;38:526-532.
36. Rennick DM, Fort MM. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2000;278:G829-G833.
37. Boismenu R, Chen Y. Insights from mouse models of colitis. J Leukoc Biol. 2000;67:267-278.
38. Breitman PL, Fonseca D, Cheung AM, et al. Isoflavones with supplemental calcium provide greater protection against the loss of bone mass and strength after ovariectomy compared to isoflavones alone. Bone. 2003;33: 597-605.
39. Sirois I, Cheung AM, Ward WE. Biomechanical bone strength and bone mass in young male and female rats fed a fish oil diet. Prostaglandins Leukot Essent Fatty Acids. 2003;68:415-421.
40. Canadian Council on Animal Care. Guide to the Care and Use of Experimental Animals, Institute of Laboratory Animal Resources Commission on Life Sciences. Ottawa, 1984.
41. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224-5231.
42. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473-1482.
43. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol. 1999;94: 878-883.
44. Einhorn TA. Bone strength: the bottom line. Calcif Tissue Int. 1992;51: 333-339.
45. van't Hof RJ. Ralston SH. Nitric oxide and bone. Immunology. 2001;103: 255-261.
46. Watkins BA, Li Y, Lippman HE, et al. Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukot Essent Fatty Acids. 2003;68:387-398.
47. Turner RT, Maran A, Lotinun S, et al. Animal models for osteoporosis. Rev Endocr Metab Disord. 2001;2:117-127.
48. Turner CH. Experimental Techniques for Bone Mechanics. In: Cowin, SC, ed. Bone Mechanics Handbook. 2nd ed. Boca Raton, FL: CRC Press, 2001:7.1-7.35.